• One Health
  • Pain Management
  • Oncology
  • Anesthesia
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

Porcine parvovirus vaccine demonstrates promise in clinical study


The platform technology, in which specific antigens are expressed by genetically modified yeast cells, was developed by the research and development team of Germany-based serYmun Yeast GmbH.

A controlled target animal study has demonstrated the protective immunization of pigs against porcine parvovirus (PPV). According to serYmun Yeast GmbH, an animal health vaccine development company based in Germany, the study’s findings are a breakthrough in the development of the first pig vaccine candidate against PPV.1

The common disease can result in reproductive failure and is endemic is most swine herds. It is often resistant to environmental degradation and many disinfectants, while persisting for at least 4 months on contaminated premises.2

Image: Dr Microbe/Adobe Stock

Image: Dr Microbe/Adobe Stock

Following 2 intramuscular injections of serYmun’s proprietary vaccine candidate, the treated group showed high titers of serum neutralizing antibodies 7 days after vaccination, and a second peak after booster immunization on day 21. In a positive control group, a recently launched commercial product of an industry-leading animal health company showed antibody titers at a comparable level. The negative control group did not show seroconversion.1

The vaccinated animals did not show any adverse clinical effects, which indicates safety of the vaccine, according to serYmun.1 “I am extremely happy and proud that our team has been successful in developing this vaccine and its basic platform technology in only 4 years”, said Wilhelm von Trott zu Solz, DVM, cofounder and CEO of serYmun Yeast GmbH, in a compnay release. “This encourages us to start the registration process to launch our PPV and other vaccines."

The yeast-based platform technology, in which specific antigens are expressed by genetically modified yeast cells, was developed by the research and development team of serYmun.1 “Based on our technology, our vaccines will benefit animals, farmers, and veterinarians enormously. Our vaccine platform allows to develop safe and polyvalent vaccines in a record time and at comparably very low costs,” said von Trott zu Solz, in the release.

serYmun Yeast will be present the findings of the study at the Animal Health, Nutrition and Technology Innovation Conference in London, March 5-8, 2023.1


  1. serYmun Yeast announces preclinical safety and efficacy data for their yeast-based vaccine against porcine parvovirus (PPV). News release. serYmun Yeast. February 27, 2023. Accessed February 28, 2023. https://www.b3cnewswire.com/202302272446/serymun-yeast-announces-preclinical-safety-and-efficacy-data-for-their-yeast-based-vaccine-against-porcine-parvovirus-ppv.html
  2. Swine manual: Parovirus. Iowa State University College of Veterinary Medicine. Accessed February 28, 2023. https://vetmed.iastate.edu/vdpam/FSVD/swine/index-diseases/parvovirus
Related Videos
Renee Schmid, DVM
Senior Bernese Mountain dog
© 2024 MJH Life Sciences

All rights reserved.